KR900012929A - 신경안정적 및/또는 정신안정적 활성을 가진 피리미디닐-피페라지닐-알킬 아졸 유도체 - Google Patents

신경안정적 및/또는 정신안정적 활성을 가진 피리미디닐-피페라지닐-알킬 아졸 유도체 Download PDF

Info

Publication number
KR900012929A
KR900012929A KR1019900001536A KR900001536A KR900012929A KR 900012929 A KR900012929 A KR 900012929A KR 1019900001536 A KR1019900001536 A KR 1019900001536A KR 900001536 A KR900001536 A KR 900001536A KR 900012929 A KR900012929 A KR 900012929A
Authority
KR
South Korea
Prior art keywords
butyl
pyrimidinyl
pyrerazinyl
pyrazole
radical
Prior art date
Application number
KR1019900001536A
Other languages
English (en)
Other versions
KR950000779B1 (ko
Inventor
꼴롬보 삐놀 아우구스또
후리골라 꼰스딴사 호로디
빠레스 꼬로미나스 후안
Original Assignee
원본미기재
라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마 filed Critical 원본미기재
Publication of KR900012929A publication Critical patent/KR900012929A/ko
Application granted granted Critical
Publication of KR950000779B1 publication Critical patent/KR950000779B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

신경안정적 및/또는 정신안정적 활성을 가진 피리미디닐-피페라지닐- 알킬 아졸 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기일반식(I)에 상응함을 특징으로 하는 신규한 헤테로 고리형 화합물.
    상기식에서 R1은 수소원자 또는 할로겐을 나타내고, n은 1 내지 6의 값을 가지며, Het는 아졸 또는 이미다졸, 인다졸, 테트라하이드로인다졸, 피라졸 및 피라졸린으로 부터 선택되는 일반식 (Ⅱ)의 아졸 유도체 중 하나를 나타내며,
    상기식에서, 언제나 상이한 A와 B는 탄소원자 또는 질소원자를 나타내고, 파선은 위치 4와 5 사이에 가능한 이중결합의 존재를 표시하고, 동일하거나 상이한 R2, R3및 R4는 방향성 또는 비방향성 다른 고리부분을 형성할수 있으며 수소원자, 할로겐, 저급알킬 라디칼, 니트로라디칼 하이드록시 라디칼, 옥시라디칼, 알콕시 라디칼, 시아노라디칼, 카르복실릭 라디칼 카르복시아미도 라디칼, 술포닉 라디칼, 아미노기가 치환되거나, 치환되지 않은 술폰아미도 라디칼, 일반식(Ⅲ)의 아민 라디칼을 나타내며,
    상기식에서, 동일하거나 상이한 R5및 R6는 수소원자, 알킬라디칼, 헤테로아릴 라디칼, 알케닐 라디칼, 알킬 카르복시라디칼, 아릴카르복시 라디칼, 알킬 술폰닐 라디칼 또는 아릴술폰닐 라디칼을 나타낸다.
  2. 제1항에 있어서 (1) 1H-피라졸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (2) 1H-피라졸-3,5-디메틸-1-(4-(4-(2-피리미디닐)-1-피리미디닐)-부틸), (3) 1H-피라졸-3,5-디메틸-4-니트로-1-(4-C4-C2-피리이디닐)-1-피페라지닐-부틸), (4) 1H-피라졸-4-메틸-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (5) 1H-인다졸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (6) 1H-피라졸-3,5-디메틸-5-브로모-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (7) 1H-피라졸-4-니트로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (8) 1H-피라졸-4-클로로-1-4-클로로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (9) 1H-피라졸-4-카르복실레이티드 에틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (10) 1H-피라조린-4-메틸-5-온-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (11) 1H-피라졸-3-메틸-5-페닐-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (12) 1H-피라졸-4-브로모-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (13) 1H-피라졸-4-시아노-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (14) 1H-피라졸-4-플루오로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (15) 1H-피라졸-4-메록시-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (16) 1H-피라졸-4-아미노-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (17) 1H-피라졸-4-메틸술폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (18) 1H-피라졸-4-벤즈아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (19) 1H-피라졸-4-에세트아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (20) 1H-피라졸-4-(2-부틸)아미노-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (21) 1H-피라졸-4-브로모-1-(4-(4-(2-브로모피리미딘-2일)-1-피레라지닐)-부틸), (22) 1H-피라졸-4-브로모-1-(4-(4-(5-클로로피리미딘-2-일)-1-피레라지닐)-부틸), (23) 1H-피라졸-5-메틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (24) 1H-피라졸-3-메틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (25) 1H-피라졸-4-브로모-5-메틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (26) 1H-피라졸-4-브로모-3-메틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (27) 1H-4,5,6,7-테트라하이드로 인다졸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (28) 2H-3,4,5,6-테트라하이드로인다졸-2-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (29) 1H-피라졸-5-메틸-1-4-페닐-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (30) 1H-피라졸-3-메틸-4-페닐-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (31) 1H-피라졸-3-클로로-4-플루오로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (32) 1H-피라졸-3-클로로-4-메톡시-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (33) 1H-피라졸-4-(4-메톡시페닐-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (34) 1H-피라졸-4-(4-클로로페닐)-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (35) 1H-피라졸-4-(1-피롤릴)-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (36) 1H-피라졸-4-페닐-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (37) 1H-피라졸-3,5-디페닐-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (38) 1H-피라졸-4-페닐설폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (39) 1H-피라졸-4-(4-메틸벤젠)술폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (40) 1H-피라졸-4-부틸술폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (41) 1H-피라졸-4-프로필술폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (42) 1H-피라졸-4-에틸술폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (43) 1H-피라졸-3.5-디메틸-4-술폰아미도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (44) 1H-피라졸-4-디메틸술폰아니도-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (45) 1H-피라졸-4-술포닉-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (46) 1H-이미다졸-1-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (47) 1H-이미다졸-2-메틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (48) 1H-아미다졸-3,4-디클로로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (49) 1H-이미다졸-4-메틸-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (50) 1H-이미다졸-5-메틸-1-(4-(2-피리미디닐)-1-피레라지닐)-부틸), (51) 1H-피라지로-4-클로로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸)하이드로클로류리, (52) 1H-피라졸-4-클로로-1-(4-(4-(2-피리미디닐)-1-피레라지닐)-부틸)디하이드로클로류리로 부터 선택되는 일반식(I)의 화합물.
  3. 하기 조작들 중 적어도 하나를 사용함을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조공정.
    3.1식에서 R1과 n은 앞서 정의한 의미를 가지며, X는 할로겐 원자 또는 메실옥시 또는 토실옥시로 부터 선택되는 탈착가능기를 나타내는 일반식(Ⅳ)의 화합물과,
    식에서, A, B, R2, R3, R4및 파선으로 표시된 결합이 앞서 정의한 의미를 가지는 일반식(Ⅴ)의 화합물과
    의 반응
    3.2 식에서, A, B, R2, R3, R4, X 및 n은 앞서 정의한 바와 같은 의미를 가지는 일반식(Ⅳ)의 화합물과,
    식에서, R1이 앞서 정의한 바와 같은 의미를 가지는 일반식(Ⅶ)의 화합물과,
    의 반응.
    3.3 식에서 R1, R2, R3, Het 및 n이 앞서 정의한 의미를 가지며, 또는 치환체 R1, 또는 R3중 적어도 하나가 수소원자를 나타내는 일반식(I)의 화합물과, 할로겐과의 반응.
    3.4 식에서 R1, Het 및 n이 앞서 정의한 의미를 가지며, R2,R3또는 R4가 니트로기를 나타내는 일반식(I)의 화합물과, R2,R3또는 R4가 아미노기를 나타내는 동일한 일반식의 화합물을 얻기 위한 환원제와의 반응.
    3.5 식에서 Het, R1, 치환체중 하나 및 n이 앞서 정의한 바와 같은 의미를 가지며, R2, R3, n 및 R4가 아미노기 또는 알킬아미노기를 나타내는 일반식(I)의 화합물과, 알킬 또는 아릴 카르복시산의 무수물, 또는 아릴 또는 알킬술폰산의 할로겐화물과의 반응.
  4. 특히 중추 신경계 이상에 대한 치료제로 사용될 약물로서, 제1 항 내지 3항중 어느한 항에 따른 일반식(I)의 유도체 또는 치료학상 허용가능한 그의 염.
  5. 허용가능한 제약학적 보조물외에 제1 항 내지 4항중 어느 한 항에 따른 일반식(I)의 적어도 한 유도체 또는 생리학상 허용가능한 그의 염을 함유하는 것을 특징으로 하는 제약학적 조성물.
  6. 불안증 치료제로서 사용될 약물의 제조, 특히 정신안정제 및/신경 안정제의 제조를 위한, 제1항 내지 5항중 어느 한 항에 따른 일반식(I)의 유도체 및 생리학상 허용가능한 그의 염의 사용.
  7. 제약학적 조성물에 결합하는 제1항에 따른 일반식(I)의 화합물 또는 생리학적으로 허용가능한 그의 염으로 구성된 정신 안정제 및/또는 신경안정제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900001536A 1989-02-09 1990-02-08 신경안정적 또는 정신안정적 활성을 가진 피리미디닐-피페라지닐-알킬아졸 유도체 KR950000779B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES89-01700 1989-02-09
FR8901700 1989-02-09
FR8901700A FR2642759B1 (fr) 1989-02-09 1989-02-09 Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante

Publications (2)

Publication Number Publication Date
KR900012929A true KR900012929A (ko) 1990-09-03
KR950000779B1 KR950000779B1 (ko) 1995-02-02

Family

ID=9378642

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900001536A KR950000779B1 (ko) 1989-02-09 1990-02-08 신경안정적 또는 정신안정적 활성을 가진 피리미디닐-피페라지닐-알킬아졸 유도체

Country Status (18)

Country Link
US (1) US5128343A (ko)
EP (1) EP0382637B1 (ko)
JP (1) JP2521170B2 (ko)
KR (1) KR950000779B1 (ko)
AT (1) ATE92059T1 (ko)
AU (1) AU623734B2 (ko)
CA (1) CA2009480A1 (ko)
DD (1) DD292000A5 (ko)
DE (1) DE69002341T2 (ko)
DK (1) DK0382637T3 (ko)
ES (1) ES2021941A6 (ko)
FR (1) FR2642759B1 (ko)
HU (1) HU204817B (ko)
NO (1) NO176880C (ko)
PT (1) PT93095B (ko)
RU (1) RU2071474C1 (ko)
YU (1) YU48071B (ko)
ZA (1) ZA90929B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219855A (en) * 1988-01-29 1993-06-15 Mitsubishi Kasei Corporation Anxiolytic drug
FR2654621B1 (fr) * 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633377A (en) * 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
FR2671972B1 (fr) * 1991-01-25 1995-03-03 Esteve Labor Dr Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
FR2763950B1 (fr) * 1997-06-02 2002-09-20 Esteve Labor Dr 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
EP1309592B9 (en) 2000-08-14 2007-02-28 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
AU8645401A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
DK1309591T3 (da) 2000-08-14 2007-03-26 Ortho Mcneil Pharm Inc Substituerede pyrazoler
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
MXPA03001960A (es) 2000-09-06 2004-03-18 Johnson & Johnson Un metodo para tratar alergias.
ES2167276B1 (es) * 2000-10-20 2003-04-01 Esteve Labor Dr Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4547499A (en) * 1984-05-10 1985-10-15 The Upjohn Company 2,4-Dihydro-2(omega-aminoalkyl)-1H-[1,2,4]triazolo[3,4-c]benzoxazin-1-one anti-allergy drug compounds, compositions and use
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity

Also Published As

Publication number Publication date
JP2521170B2 (ja) 1996-07-31
ATE92059T1 (de) 1993-08-15
NO176880B (no) 1995-03-06
ZA90929B (en) 1990-11-28
NO900411L (no) 1990-08-10
AU4919290A (en) 1990-08-16
DD292000A5 (de) 1991-07-18
AU623734B2 (en) 1992-05-21
ES2021941A6 (es) 1991-11-16
PT93095A (pt) 1990-08-31
CA2009480A1 (fr) 1990-08-09
EP0382637B1 (en) 1993-07-28
YU25790A (en) 1991-08-31
US5128343A (en) 1992-07-07
FR2642759B1 (fr) 1991-05-17
EP0382637A1 (fr) 1990-08-16
DE69002341D1 (de) 1993-09-02
NO900411D0 (no) 1990-01-29
KR950000779B1 (ko) 1995-02-02
YU48071B (sh) 1997-01-08
DE69002341T2 (de) 1993-12-02
RU2071474C1 (ru) 1997-01-10
HU900716D0 (en) 1990-04-28
JPH032179A (ja) 1991-01-08
HU204817B (en) 1992-02-28
DK0382637T3 (da) 1993-09-20
PT93095B (pt) 1995-12-29
NO176880C (no) 1995-06-14
FR2642759A1 (fr) 1990-08-10
HUT53100A (en) 1990-09-28

Similar Documents

Publication Publication Date Title
KR900012929A (ko) 신경안정적 및/또는 정신안정적 활성을 가진 피리미디닐-피페라지닐-알킬 아졸 유도체
AU655544B2 (en) Azole compounds, their production and use
US4507488A (en) N-Pyrazolylalkylenediamine intermediates
EP0456835B1 (en) Quinazoline-3-alkanoic acid derivative, salt thereof, and production thereof
CA2195107A1 (en) Azetidine, pyrrolidine and piperidine derivatives
US4584383A (en) Substituted 2-mercapto-imidazoles and their preparation
JP2003509462A (ja) トロンボポイエチン模倣物
KR20050044577A (ko) 11-베타-히드록시 스테로이드 탈수소효소 제1형의 억제제
PT1215210E (pt) Benzofuranos
KR19990063989A (ko) 염증 치료용의 1,3,5-삼치환된 피라졸 화합물
KR0183028B1 (ko) 벤즈이미다졸 유도체, 그 제조방법 및 의약물로서의 사용방법
CZ282096A3 (en) Thiazolidines and oxazolidines substituted by pyridine ring and their application as hypoglycaemic agents
US4436913A (en) 1H- and 2H- indazole derivatives
US3250761A (en) New sulfonamides
KR920002581A (ko) 1-디페닐메틸 피페라진 유도체, 그 제조방법 및 의약물로의 이용
US4038410A (en) Nitroimidazole derivatives and process for the preparation thereof
BG98896A (bg) Алкилови производни на тразодона
US3291793A (en) Sulfonamides
EP0030371A1 (en) N-substituted imidazole derivatives, a process for their preparation, antifungal compositions comprising them and their use for preparing such compositions
EP0427860A1 (en) New imidazole derivatives, production thereof, and uses thereof as medicines
JPH01249755A (ja) 新規な２−アゾリル−１−シクロプロピルエタノール誘導体およびその塩
JPH0819110B2 (ja) 新規なイミダゾール誘導体もしくはその塩およびそれらを含有する抗炎症剤、解熱鎮痛剤または抗関節炎剤
JPS6185369A (ja) １，２，４−トリアゾ−ル誘導体
EP0388659A1 (en) Azole-1-alkanamides as antiarrhythmic agents and preparation thereof
JP2001163892A (ja) アゾール誘導体又はその塩

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010118

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee